DOCSLIB.ORG

Induced Liver Injury

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Induced Liver Injury A Wholly-Owned Subsidiary of Frontage Laboratories, Inc. Novel BSEP and MDR3 Inhibition Assays for Investigating Drug- Induced Liver Injury Kan He, PhD Outline • BSEPcyte®: BSEP inhibition format • MDR3cyte®: MDR3 inhibition format Why BSEP • Physiologically important: BSEP is the primary mechanism for export of bile salts – The driving force for bile salt enterohepatic recirculation and bile flow – “Vacuum cleaner” to maintain low intracellular level of bile salts • Validated target with clinical phenotype: BSEP mutations lead to human liver diseases – Progressive Familial Intrahepatic Cholestasis 2 (K903X, Intron 4 (+3)A>C) • Liver failure, death – Benign Recurrent Intrahepatic Cholestasis type 2 (E297G, R432T, V444A) – Associated with intrahepatic cholestasis of pregnancy • BSEP inhibition associated with Drug induced liver injury (DILI) DILI accounts for >50% acute liver failures, and is the leading cause of failures in drug development, boxed warnings on marketed drugs, and market withdrawals of approved drugs. Inhibition of BSEP and MDR3 is one of the underlying mechanisms for DILI. It has been an important task to develop physiologically relevant, reliable, higher throughput assays to determine the inhibition of BSEP and MDR3. Biotranex – Accurate. Efficient. Innovative Why BSEPcyte® • To address concerns about • BSEPcyte® is a physiologically other BSEP inhibition assays relevant, hepatocyte-based, – BSEP-transfected Sf9 insect cell high throughput assay membrane vesicles • Artificial membrane uptake system – Primary hepatocytes in • Incapable of evaluating BSEP suspension inhibition by metabolites • Physiologically relevant • Questionable physiologically – IVIVC relevance • Efflux – Human sandwich-cultured • hepatocytes In-situ metabolism • Reproducible, sensitive, dynamic • Technical challenges range • Low throughput • Flexible – Others • High-throughput • BSEP and sodium taurocholate transporter co-transfected kidney cells • Species comparison • Xenopus laevis oocytes • Canalicular membrane vesicles (CMV) Cheng Y, et al. Chem Biol Interact, 2015 Biotranex – Accurate. Efficient. Innovative BSEPcyte® Assay Principle Bile Acids (pKa: 5-6.5) Cholesterol CYP7A1 CYP27A1 CYP7B1 (Neutral BACS HSD3B7 Pathway) (Acidic Bile Acids VLCS CYP8B1 Pathway) AMACR AKR1D1 BCOX AKR1D4 BDP CYP27A1 Hepatocyte BAAT SCPx CA-CoA/CDCA-CoA Bile Salts BAAT BSEP Bile Salts (pKa: 1-4) >99% Bile salts exported by BSEP in human liver. CA: R1 = OH Jansen et al. Gastroenterology. 1999;117:1370-9 CDCA: R = H 1 BSEPcyte® Protected by US patent No 9,772,325 GCA/GCDCA: R2 = NHCH2COOH TCA/TCDCA: R = NHCH CH SO H 2 2 2 3 Information: [email protected] Physiological Bile Acid Conjugation Reactions DCA CA GCA GDCA TDCA TCA CDCA LCA GLCA GCDCA TCDCA TLCA Biotranex – Accurate. Efficient. Innovative BSEP IC50: BSEPcyte® vs Membrane Vesicles (MV) Total 86 drugs BSEPcyte® ➢ Detected more most-DILI- concern drugs than MV • metabolism-mediated • drug accumulation ➢ Produced physiologically relevant IC50 values ➢ Produced results highly correlated with cholestatic and mixed liver injury Zhang J, et al. Chem Biol Interact, 2016 Biotranex – Accurate. Efficient. Innovative BSEPcyte®: Most-DILI Concern Drugs Compound Name DILIConcern Label Section IC50 (µM) Cmax/IC50 ritonavir Most-DILI-Concern Warnings and precautions 0.2 37.8 deferasirox Most-DILI-Concern Box warning 11.9 14.2 troglitazone Most-DILI-Concern Withdrawn 0.5 12.8 cyclosporine Most-DILI-Concern Warnings and precautions 0.1 7.8 indinavir Most-DILI-Concern Warnings and precautions 2.8 4.7 ketoconazole Most-DILI-Concern Box warning 1.5 4.7 fasiglifam Most-DILI-Concern Discontinued 2.8 3.6 benziodarone Most-DILI-Concern Withdrawn 0.8 2.4 benzbromarone Most-DILI-Concern Withdrawn 2.8 1.5 etodolac Most-DILI-Concern Warnings and precautions 83.9 0.82 bosentan Most-DILI-Concern Box warning 9.2 0.81 lumiracoxib Most-DILI-Concern Withdrawn 45.6 0.69 leflunomide Most-DILI-Concern Box warning 50.0 0.50 disulfiram Most-DILI-Concern Warnings and precautions 12.0 0.45 diclofenac Most-DILI-Concern Warnings and precautions 31.8 0.21 bromfenac Most-DILI-Concern Withdrawn 93.3 0.19 itraconazole Most-DILI-Concern Warnings and precautions 3.1 0.13 ticlopidine Most-DILI-Concern Warnings and precautions 82.0 0.10 ciglitazone Most-DILI-Concern Discontinued 0.8 ? fipexide Most-DILI-Concern Withdrawn 4.9 (600 mg dose) saquinavir Less-DILI-Concern Warnings and precautions 0.4 13.6 rosiglitazone Less-DILI-Concern Warnings and precautions 0.2 5.2 pioglitazone Less-DILI-Concern Warnings and precautions 1.4 2.1 chlorpromazine Less-DILI-Concern Adverse reactions 6.4 0.15 trazodone Less-DILI-Concern Adverse reactions 43.0 0.12 BSEP IC50: BSEPcyte® vs Membrane Vesicles (MV) BSEPcyte ® MDR3cyte ® MV BSEP MRP2 MRP3 MRP4 Compound Name (uM) (uM) (uM) (uM) (uM) (uM) LOVASTATIN 2 17 19.3 133 133 133 REPAGLINIDE 1 18 22 72.3 16.7 53.9 FLUVASTATIN 1 >100 36.1 stimulation 57 133 NIFEDIPINE 2 23 64 133 133 16.6 DONEPEZIL 9 3 78 133 133 72.9 stimulation ACITRETIN 0.04 >100 38.2 133 49.00 /inhibition GLIMEPIRIDE >100 >100 15.7 stimulation 6.39 64 DANAZOL >100 >100 18.7 133 133 133 INDOMETHACIN 11 12 42 stimulation 66 5.8 Additional 250 drugs AMIODARONE >100 >100 43 133 133 133 ENTACAPONE 10 >100 55.6 133 35.1 6.8 BENZBROMARONE 0 1 17.5 41.6 133 17 INDINAVIR >100 >100 21.2 133 83 133 KETOCONAZOLE 0 1 3.4 133 133 69 CLOFIBRATE >100 >100 71 133 133 133 LOPINAVIR 0 >100 17.3 133 21 47 BSEPcyte® DICLOXACILLIN 7 >100 56.4 133 133 133 FENOFIBRATE >100 >100 15.3 133 133 133 ➢ Detected more most-DILI- PIOGLITAZONE <0.3 >100 0.4 stimulation 133 49.5 CHLORDIAZEPOXIDE 58 8 44.1 133 133 133 MELOXICAM 55 15 77.5 stimulation 133 133 QUINAPRIL >100 >100 94 stimulation 133 133 concern drugs than MV OXAPROZIN >100 >100 133 133 133 12 NITROFURANTOIN >100 62 133 133 133 20.9 NALIDIXIC ACID >100 >100 133 133 133 57.5 ACETAZOLAMIDE >100 >100 133 133 133 133 • metabolism-mediated ALLOPURINOL >100 >100 133 133 133 133 AMITRIPTYLINE 10 6 133 133 133 133 AMLODIPINE 1 4 133 133 133 133 AMOXICILLIN >100 >100 133 133 133 133 • drug accumulation AZATHIOPRINE >100 >100 133 133 133 133 CAPTOPRIL >100 >100 133 133 133 133 CARBAMAZEPINE 116 85 133 133 133 133 CARVEDILOL 1 0 133 133 133 133 ➢ Produced physiologically CEFACLOR >100 >100 133 133 133 133 CELECOXIB 12 >100 133 133 133 133 CHLORAMBUCIL 23 >100 133 133 133 133 CHLORAMPHENICOL >100 >100 133 stimulation 133 133 relevant IC50 values CHLORPHENIRAMINE 110 4 133 133 133 133 CHLORPROMAZINE 3 1 133 133 133 133 CHLORPROPAMIDE >100 >100 133 133 133 133 CIMETIDINE >100 >100 133 133 133 133 ➢ Produced results highly CIPROFLOXACIN >100 >100 133 133 133 133 CISPLATIN >100 1 133 133 133 133 CITALOPRAM 56 6 133 133 133 133 CLOZAPINE 10 1 133 133 133 133 correlated with cholestatic DESIPRAMINE 7 3 133 133 133 133 DOXEPIN 10 6 133 133 133 133 EFAVIRENZ 2 5 133 133 133 133 EPROSARTAN >100 >100 133 57.9 6.65 133 and mixed liver injury ERYTHROMYCIN 117 >100 133 133 133 133 ETHACRYNIC ACID 29 >100 133 3.85 95.9 133 FLUCONAZOLE >100 >100 133 133 133 133 FLUOXETINE 1 3 133 133 133 133 FLUTAMIDE 1 >100 133 133 133 133 GEMFIBROZIL 39 >100 133 stimulation 133 133 GLICLAZIDE >100 >100 133 133 133 133 GLIPIZIDE >100 >100 133 133 133 133 HALOPERIDOL >100 16 133 133 133 133 IMIPRAMINE 15 6 133 133 133 133 INDAPAMIDE 25 35 133 133 133 133 IPRONIAZID >100 >100 133 133 133 133 LAMIVUDINE >100 >100 133 133 133 133 LANSOPRAZOLE 8 12 133 133 133 133 LEFLUNOMIDE 20 88 133 133 133 133 LEVOFLOXACIN >100 >100 133 133 133 133 LOMUSTINE 21 30 133 133 133 133 MEROPENEM >100 >100 133 133 133 133 METHIMAZOLE >100 >100 133 133 133 133 METRONIDAZOLE >100 >100 133 133 133 133 MEXILETINE 268 122 133 133 133 133 MIRTAZAPINE 20 17 133 133 133 133 NAPROXEN >100 >100 133 133 133 133 NEVIRAPINE 73 >100 133 133 133 133 NIMESULIDE 7 16 133 133 133 133 NORTRIPTYLINE 15 1 133 133 133 133 OFLOXACIN >100 >100 133 133 133 133 OLANZAPINE >100 >100 133 133 133 133 OXCARBAZEPINE >100 >100 133 133 133 133 Yucha, et al. Toxicol Sci, 2017 PIROXICAM 17 >100 133 133 133 133 PREGABALIN >100 >100 133 133 133 133 PROPAFENONE 6 2 133 133 133 133 RAMIPRIL >100 >100 133 133 133 133 He, et al. (To be published) RANITIDINE >100 177 133 133 133 133 LAMOTRIGINE 126 74 133 not tested not tested not tested Biotranex – Accurate. Efficient. Innovative BSEPcyte®: Species Difference in BSEP Inhibition (IC50, µM) Drug Human Monkey Dog Rat Mouse Haloperidol 25.6 64 73 54 >100 Ticlopidine 82 >100 >100 >100 >100 Saquinavir 0.4 3.1 3.5 5.1 >100 Atorvastatin 2.6 0.6 0.9 0.2 31.7 Azathioprine >1000 >100 >100 >100 >100 Cerivastatin 3.9 0.99 8.8 1.9 26.5 Chlorpromazine 44.3 7.28 29.4 13.1 136.6 Cyclosporine 0.1 0.71 2.4 0.5 4.69 Enalapril >1000 >100 >100 >100 >100 Etodolac 83.9 >100 >100 >100 >100 Fenofibrate 61 126.5 89 178.6 >100 Glimepiride 14.1 5.3 12.3 1.5 >100 Griseofulvin 756.9 43.5 85.8 45.7 >100 Imipramine 185.2 106.1 171.3 169.3 >100 Ketoconazole 1.5 4.4 7.5 4.1 >100 Lovastatin 1.7 14 15.9 14.2 >100 Methimazole >1000 >100 >100 >100 >100 Norfloxacin >1000 >100 >100 >100 >100 Piroxicam 151.4 182.4 >100 >100 >100 Ritonavir 0.21 1.2 1.7 0.5 5.7 Rosiglitazone 0.23 5 24.4 9.5 >100 Sulindac 122.9 >100 >100 >100 >100 Trazodone 42.9 134 >100 186 >100 Troglitazone 0.48 1.4 4.6 4.9 65.4 Zhang J, et al.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies
    Chinese Journal of Physiology 61(1): 1-13, 2018 1 DOI: 10.4077/CJP.2018.BAG516 Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies Tzu-Tung Chang, Chia-Jung Yang, Yu-Chi Lee, and Sheng-Nan Wu Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan, Republic of China Abstract Telmisartan (Tel) is recognized as a non-peptide blocker of AT1R. Whether this agent has any direct effects on ion currents remains unexplored. In whole-cell current recordings, addition of Tel + increased the peak amplitude of voltage-gated Na (NaV) current (INa) accompanied by the increased time constant of INa inactivation in differentiated NSC-34 motor neuron-like cells. Tel-stimulated INa in these cells is unlinked to either blockade of AT1R or activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). In order to explore how this compound affects the amplitude and kinetics of INa in neurons, a Hodgkin-Huxley-based (HH-based) model designed to mimic effect of Tel on the functional activities of neurons was computationally created in this study. In this framework, the parameter for h inactivation gating variable, which was changed in a stepwise fashion, was implemented + + to predict changes in membrane potentials (V) as a function of maximal Na (GNa), K conductance (GK), or both. As inactivation time course of INa was increased, the bifurcation point of V versus GNa became lower, and the range between subcritical and supercritical values at the bifurcation of V versus GK correspondingly became larger.
    [Show full text]
  • REVIEW Peroxisome Proliferator-Activated Receptors In
    199 REVIEW Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition P Froment, F Gizard1, D Defever2, B Staels1, J Dupont3 and P Monget3 INSERM U.418, UMR Communications Cellulaire et Différenciation, Hôpital Debrousse, 29 rue Soeur Bouvier, 69322 Lyon, France 1INSERM U.545, Institut Pasteur de Lille et Faculté de Pharmacie Université de Lille 2, 1 rue du Pr Calmette, 59019 Lille, France 2LMCB, Department of Molecular Biomedical Research, V.I.B., Technologiepark 927, B-9052 Ghent (Zwijnaarde), Belgium 3Physiologie de la reproduction et des comportements, UMR 6175 INRA-CNRS-Université F. Rabelais de Tours-Haras Nationaux, 37380 Nouzilly, France (Requests for offprints should be addressed to P Froment; [email protected]) Abstract Peroxisome proliferator-activated receptors (PPAR, granulosa cell proliferation and steroidogenesis in vitro. All PPAR/ and PPAR) are a family of nuclear receptors these recent data raise new questions about the biologic that are activated by binding of natural ligands, such as actions of PPARs in reproduction and their use in polyunsaturated fatty acids or by synthetic ligands. Syn- therapeutic treatments of fertility troubles such as PCOS thetic molecules of the glitazone family, which bind to or endometriosis. In this review, we first describe the roles PPAR, are currently used to treat type II diabetes and of PPARs in different compartments of the reproductive also to attenuate the secondary clinical symptoms fre- axis (from male and female gametogenesis to parturition), quently associated with insulin resistance, including poly- with a focus on PPAR. Secondly, we discuss the possible cystic ovary syndrome (PCOS). PPARs are expressed molecular mechanisms underlying the effect of glitazones in different compartments of the reproductive system on PCOS.
    [Show full text]
  • Endocrine Drugs
    PharmacologyPharmacologyPharmacology DrugsDrugs thatthat AffectAffect thethe EndocrineEndocrine SystemSystem TopicsTopicsTopics •• Pituitary Pituitary DrugsDrugs •• Parathyroid/Thyroid Parathyroid/Thyroid DrugsDrugs •• Adrenal Adrenal DrugsDrugs •• Pancreatic Pancreatic DrugsDrugs •• Reproductive Reproductive DrugsDrugs •• Sexual Sexual BehaviorBehavior DrugsDrugs FunctionsFunctionsFunctions •• Regulation Regulation •• Control Control GlandsGlandsGlands ExocrineExocrine EndocrineEndocrine •• Secrete Secrete enzymesenzymes •• Secrete Secrete hormoneshormones •• Close Close toto organsorgans •• Transport Transport viavia bloodstreambloodstream •• Require Require receptorsreceptors NervousNervous EndocrineEndocrine WiredWired WirelessWireless NeurotransmittersNeurotransmitters HormonesHormones ShortShort DistanceDistance LongLong Distance Distance ClosenessCloseness ReceptorReceptor Specificity Specificity RapidRapid OnsetOnset DelayedDelayed Onset Onset ShortShort DurationDuration ProlongedProlonged Duration Duration RapidRapid ResponseResponse RegulationRegulation MechanismMechanismMechanism ofofof ActionActionAction HypothalamusHypothalamusHypothalamus HypothalamicHypothalamicHypothalamic ControlControlControl PituitaryPituitaryPituitary PosteriorPosteriorPosterior PituitaryPituitaryPituitary Target Actions Oxytocin Uterus ↑ Contraction Mammary ↑ Milk let-down ADH Kidneys ↑ Water reabsorption AnteriorAnteriorAnterior PituitaryPituitaryPituitary Target Action GH Most tissue ↑ Growth TSH Thyroid ↑ TH secretion ACTH Adrenal ↑ Cortisol Cortex
    [Show full text]
  • Effect of Chronic Treatment with Rosiglitazone on Leydig Cell Steroidogenesis in Rats
    Couto et al. Reproductive Biology and Endocrinology 2010, 8:13 http://www.rbej.com/content/8/1/13 RESEARCH Open Access Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: In vivo and ex vivo studies Janaína A Couto1, Karina LA Saraiva2, Cleiton D Barros3, Daniel P Udrisar4, Christina A Peixoto2, Juliany SB César Vieira4, Maria C Lima3, Suely L Galdino3, Ivan R Pitta3, Maria I Wanderley4* Abstract Background: The present study was designed to examine the effect of chronic treatment with rosiglitazone - thiazolidinedione used in the treatment of type 2 diabetes mellitus for its insulin sensitizing effects - on the Leydig cell steroidogenic capacity and expression of the steroidogenic acute regulatory protein (StAR) and cholesterol side-chain cleavage enzyme (P450scc) in normal adult rats. Methods: Twelve adult male Wistar rats were treated with rosiglitazone (5 mg/kg) administered by gavage for 15 days. Twelve control animals were treated with the vehicle. The ability of rosiglitazone to directly affect the production of testosterone by Leydig cells ex vivo was evaluated using isolated Leydig cells from rosiglitazone- treated rats. Testosterone production was induced either by activators of the cAMP/PKA pathway (hCG and dbcAMP) or substrates of steroidogenesis [22(R)-hydroxy-cholesterol (22(R)-OH-C), which is a substrate for the P450scc enzyme, and pregnenolone, which is the product of the P450scc-catalyzed step]. Testosterone in plasma and in incubation medium was measured by radioimmunoassay. The StAR and P450scc expression was detected by immunocytochemistry. Results: The levels of total circulating testosterone were not altered by rosiglitazone treatment. A decrease in basal or induced testosterone production occurred in the Leydig cells of rosiglitazone-treated rats.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • AVANDIA® (Rosiglitazone Maleate) Tablets
    PRESCRIBING INFORMATION AVANDIA® (rosiglitazone maleate) Tablets WARNING: CONGESTIVE HEART FAILURE ● Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure in some patients (see WARNINGS). After initiation of AVANDIA, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, the heart failure should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of AVANDIA must be considered. ● AVANDIA is not recommended in patients with symptomatic heart failure. Initiation of AVANDIA in patients with established NYHA Class III or IV heart failure is contraindicated. (See CONTRAINDICATIONS and WARNINGS.) DESCRIPTION AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. AVANDIA is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adult-onset diabetes). AVANDIA improves glycemic control while reducing circulating insulin levels. Pharmacological studies in animal models indicate that rosiglitazone improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors. Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2- pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, (Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base). The molecule has a single chiral center and is present as a racemate. Due to rapid interconversion, the enantiomers are functionally indistinguishable. The structural formula of rosiglitazone maleate is: The molecular formula is C18H19N3O3S•C4H4O4.
    [Show full text]
  • Inhibition of Mitochondrial Fatty Acid Oxidation in Drug-Induced Hepatic Steatosis*
    Liver Research 3 (2019) 157e169 Contents lists available at ScienceDirect Liver Research journal homepage: http://www.keaipublishing.com/en/journals/liver-research Review Article Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis* Bernard Fromenty INSERM, UMR 1241, Universite de Rennes 1, Rennes, France article info abstract Article history: Mitochondrial fatty acid oxidation (mtFAO) is a key metabolic pathway required for energy production in Received 17 April 2019 the liver, in particular during periods of fasting. One major consequence of drug-induced impairment of Received in revised form mtFAO is hepatic steatosis, which is characterized by an accumulation of triglycerides and other lipid 16 May 2019 species, such as acyl-carnitines. Actually, the severity of this liver lesion is dependent on the residual Accepted 14 June 2019 mitochondrial b-oxidation flux. Indeed, a severe inhibition of mtFAO leads to microvesicular steatosis, hypoglycemia and liver failure. In contrast, moderate impairment of mtFAO can cause macrovacuolar Keywords: steatosis, which is a benign lesion in the short term. Because some drugs can induce both microvesicular Drug-induced liver injury (DILI) Steatosis and macrovacuolar steatosis, it is surmised that severe mitochondrial dysfunction could be favored in Mitochondria some patients by non-genetic factors (e.g., high doses and polymedication), or genetic predispositions b-Oxidation involving genes that encode proteins playing directly or indirectly a role in the mtFAO pathway. Example Acetaminophen (APAP) of drugs inducing steatosis include acetaminophen (APAP), amiodarone, ibuprofen, linezolid, nucleoside Troglitazone reverse transcriptase inhibitors, such as stavudine and didanosine, perhexiline, tamoxifen, tetracyclines, troglitazone and valproic acid. Because several previous articles reviewed in depth the mechanism(s) whereby most of these drugs are able to inhibit mtFAO and induce steatosis, the present review is rather focused on APAP, linezolid and troglitazone.
    [Show full text]
  • Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
    PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28
    [Show full text]
  • Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Final, July 2009
    Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2009 Drug Safety Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 51, rm. 2201 Silver Spring, MD 20993-0002 Tel: 301-796-3400; Fax: 301-847-8714; E-mail: [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or Office of Communication, Outreach, and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 Tel: 800-835-4709 or 301-827-1800 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2009 Drug Safety TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND: DILI ................................................................................................... 2 III. SIGNALS OF DILI AND HY’S
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]